SYDNEY, AUSTRALIA: Botanix Pharmaceuticals Limited (ASX: BOT), a company that specializes in clinical dermatology, has announced the promotion of Dr Howie McKibbon to the position of Chief Executive Officer, effective from 24 August 2023 (Arizona time).

Dr McKibbon has been serving as the Chief Operating Officer of the Company, and he will continue to report to the Executive Chairman, Vince Ippolito.

The Board remains unchanged by this appointment. Dr McKibbon has a long and successful career in the pharmaceutical industry, spanning over 25 years.

He has worked with Mr Ippolito in several dermatology companies before joining Botanix as the Chief Commercial Officer. He has played a key role in the development and commercialization of Sofpironium Bromide, the Company’s lead product for excessive sweating.

Mr Ippolito congratulated Dr McKibbon on his new role and expressed his confidence in his leadership and vision for the Company.

He said: “Howie is an outstanding leader and a proven performer in medical dermatology. He has been instrumental in bringing Sofpironium Bromide to the verge of FDA approval and launch, and he is well prepared to take Botanix to the next level of growth and success. I have had the honor of working with Howie for more than a decade and I am delighted to see him take on this challenge. I look forward to supporting him and the Botanix team as we build the world’s most successful independent dermatology company.”

Dr McKibbon thanked Mr Ippolito and the Board for their trust and support, and said he was excited to lead Botanix at this critical juncture.

He said: “Botanix is a unique and innovative company with a strong pipeline of products that address unmet needs in dermatology. I am privileged to be appointed as the CEO and to work with such a talented and dedicated team. We are on track to achieve FDA approval for Sofpironium Bromide by late 3Q 2023, and we are ready to launch it in early 2024, following the completion of our payer, distribution, and sales and marketing activities. We have a huge opportunity ahead of us and I am confident that we will deliver value for our shareholders, customers, and patients.”